The fate of Sprout Pharmaceuticals Inc.’s Addyi (flibanserin) for treatment of female hypoactive sexual desire disorder may hinge on whether, and how, the risks of a serious interaction with alcohol can be managed.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?